Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 938 participants.
Also called NCT06449235
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 938 participants
- Sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- Registry
-
NCT06449235
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Bangladesh
- Registry status
- Unknown status
Technical summary
Registry record NCT06449235. Non-randomized; no masking; primary purpose treatment. Start 2024-09 (anticipated); primary completion 2025-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
- Condition
- Type2diabetes
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Sulphonylureas
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Other DPP4-i
- Intervention (Drug)
- Thiazolidinediones
- Intervention (Drug)
- Alpha-Glucosidase Inhibitor
- Intervention (Drug)
- Glucagon-Like Peptide-1
- Intervention (Drug)
- Receptor Agonists (GLP1RA)
- Intervention (Drug)
- SGLT2 inhibitors
- Lead sponsor
- Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- Collaborator
- Pi Research and Development Center
- Collaborator
- Acme Laboratories Ltd.
Record details
- Record id
cardio:ct-nct06449235- Content hash
8fc6286e7fa0257112bfc46d700be1d22f46a48ebc100972c06e93f78e1c7c6a